Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
28th March 2025 Uncategorised 0A rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio, and the company’s board is “carefully reviewing” the offer, which values the biotech 50% higher than the original deal.
More: Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer
Source: fierce